Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada.

Klinke JA, Johnson JA, Guirguis LM, Toth EL, Lee TK, Lewanczuk RZ, Majumdar SR.

Clin Ther. 2004 Mar;26(3):439-46.

PMID:
15110137
2.

Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus.

Supina AL, Guirguis LM, Majumdar SR, Lewanczuk RZ, Lee TK, Toth EL, Johnson JA.

Clin Ther. 2004 Apr;26(4):598-606.

PMID:
15189757
3.

Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.

Bulatova NR, Yousef AM, AbuRuz SM.

Thromb Res. 2007;121(1):43-50. Epub 2007 Apr 25.

PMID:
17462716
4.

Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus.

Colwell JA.

Am J Cardiovasc Drugs. 2004;4(2):87-106. Review.

PMID:
15049721
5.

Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk--results from the VALSIM Study.

Fiuza M, Cortez-Dias N, Martins S, Belo A; VALSIM study investigators.

Rev Port Cardiol. 2008 Dec;27(12):1495-529. English, Portuguese.

6.

Aspirin for primary prevention in patients with diabetes mellitus.

Nguyen KX, Marinac JS, Sun C.

Fam Med. 2005 Feb;37(2):112-7.

7.

Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.

Bruno A, Grassi G, Dani F, Degiovanni M, Maghenzani G, Pagano G.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6.

PMID:
15871850
8.

Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement.

Toth EL, Majumdar SR, Guirguis LM, Lewanczuk RZ, Lee TK, Johnson JA.

Pharmacotherapy. 2003 May;23(5):659-65.

PMID:
12741441
10.

Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.

Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG; Canadian ACS Registries Investigators.

Am Heart J. 2007 Dec;154(6):1108-15. Epub 2007 Sep 14.

PMID:
18035083
11.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

12.

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.

Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators.

Eur Heart J. 2007 Sep;28(18):2200-7. Epub 2007 Aug 2.

PMID:
17673448
13.

Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.

Savonitto S, Ambrosini V, Marzocchi A, Tolaro S, Petronio AS, Galassi AR, Bongo AS, Gaglione A, Bolognese L; IDEA Survey Investigators; Italian Society of Invasive Cardiology.

Ital Heart J. 2005 Feb;6(2):106-18.

PMID:
15819503
14.

Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.

Duzenli MA, Ozdemir K, Aygul N, Soylu A, Tokac M.

Am J Cardiol. 2008 Aug 15;102(4):396-400. doi: 10.1016/j.amjcard.2008.03.074. Epub 2008 May 22.

PMID:
18678294
15.

Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.

Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, Kesmarky G, Czopf L, Toth K.

Drugs Aging. 2006;23(7):559-67.

PMID:
16930084
16.

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.

Cull CA, Neil HA, Holman RR.

Diabet Med. 2004 Dec;21(12):1368-71.

PMID:
15569143
17.

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A.

J Am Coll Cardiol. 2007 Oct 16;50(16):1541-7. Epub 2007 Oct 1.

18.

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators.

Circulation. 2008 Oct 14;118(16):1626-36. doi: 10.1161/CIRCULATIONAHA.108.791061. Epub 2008 Aug 31.

19.

Aspirin use among adults with diabetes: recent trends and emerging sex disparities.

Persell SD, Baker DW.

Arch Intern Med. 2004 Dec 13-27;164(22):2492-9.

PMID:
15596642
20.

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.

Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ; CHARISMA Investigators.

Ann Intern Med. 2009 Mar 17;150(6):379-86.

PMID:
19293071

Supplemental Content

Support Center